Muhammed Rahaman

Dr Muhammed Rahaman

Research Associate

Centre for Cancer Biology

College of Health

Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.

With a background in Preclinical Pharmacology, Muhammed obtained his PhD from the University of South Australia. Currently, he is working as a postdoctoral researcher at the Cancer Pharmacogenomics Laboratory at the Centre for Cancer Biology. His research focuses on genomic instability in cancer cells and utilizing this to identify new drug targets for treatment. He previously worked with Professor Shudong Wang in the Drug Discovery and Development group at the University of South Australia. He has extensive experience in the preclinical development of novel anti-cancer targeted agents, particularly cyclin-dependent kinase inhibitors, using both in vitro and in vivo models of cancer.

Year Citation
2025 Mekonnen, L. B., Teo, T., Noll, B., Rahaman, M. H., Lenjisa, J., Basnet, S., . . . Wang, S. (2025). A brain-penetrant CDK4/6 inhibitor - AU3-14 shows robust anti-tumor efficacy against glioblastoma.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 189(118340), 118340.
DOI Europe PMC1
2025 Safaroghli-azar, A., Mekonnen, L. B., Hassankhani, R., Lenjisa, J., Basnet, S. K. C., Batayneh, H., . . . Wang, S. (2025). A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast Cancer. Investigational New Drugs, 43(3), 728-741.
DOI
2024 Rahman, R., Rahaman, M. H., Hanson, A. R., Choo, N., Hassankhani, R., Islam, S., . . . Selth, L. A. (2024). CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer. British Journal of Cancer, 131(6), 1092-1105.
DOI Scopus3 WoS4 Europe PMC5
2024 Rahman, R., Rahaman, M. H., Hanson, A. R., Choo, N., Xie, J., Townley, S. L., . . . Selth, L. A. (2024). Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.. Br J Cancer, 131(10), 1719.
DOI WoS1 Europe PMC1
2023 Islam, S., Rahaman, M. H., Yu, M., Noll, B., Martin, J. H., Wang, S., & Head, R. (2023). Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition. Cancers, 15(4), 21 pages.
DOI Scopus5 WoS4 Europe PMC5
2021 Yu, M., Teo, T., Yang, Y., Li, M., Long, Y., Philip, S., . . . Wang, S. (2021). Potent and orally bioavailable CDK8 inhibitors: design, synthesis, structure-activity relationship analysis and biological evaluation. European Journal of Medicinal Chemistry, 214, 1-22.
DOI Scopus14 WoS13 Europe PMC11
2020 Emadi, F., Teo, T., Rahaman, M. H., & Wang, S. (2020). CDK12: a potential therapeutic target in cancer. Drug Discovery Today, 25(12), 2257-2267.
DOI Scopus29 WoS29 Europe PMC24
2019 Rahaman, M. H., Yu, Y., Zhong, L., Adams, J., Lam, F., Li, P., . . . Wang, S. (2019). CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia. Investigational new drugs, 37(4), 625-635.
DOI Scopus34 WoS33 Europe PMC27
2019 Rahaman, M. H., Lam, F., Zhong, L., Teo, T., Adams, J., Yu, M., . . . Wang, S. (2019). Targeting CDK9 for treatment of colorectal cancer. Molecular Oncology, 13(10), 16 pages.
DOI Scopus45 WoS43 Europe PMC40
2017 Tadesse, S., Yu, M., Mekonnen, L. B., Lam, F., Islam, S., Tomusange, K., . . . Wang, S. (2017). Highly potent, selective, and orally bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation. Journal of medicinal chemistry, 60(5), 1892-1915.
DOI Scopus72 WoS65 Europe PMC40
2017 Diab, S., Abdelaziz, A. M., Li, P., Teo, T., Basnet, S. K. C., Noll, B., . . . Wang, S. (2017). Dual inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia. European journal of medicinal chemistry, 139, 762-772.
DOI Scopus23 WoS22 Europe PMC19
2016 Rahaman, M. H., Kumarasiri, M., Mekonnen, L. B., Yu, M., Diab, S., Albrecht, H., . . . Wang, S. (2016). Targeting CDK9: A promising therapeutic opportunity in prostate cancer. Endocrine Related Cancer, 23(12), T211-T226.
DOI Scopus63 WoS58 Europe PMC53
2015 Li, K. L., Bray, S. C., Iarossi, D., Adams, J., Zhong, L., Noll, B., . . . D'Andrea, R. J. (2015). Investigation of a novel cyclin-dependent-kinase (CDK) inhibitor Cdki-73 as an effective treatment option for MLL-AML. Blood, 126(23), 1365.
DOI WoS5
2014 Parvin, F., Islam Md, J., Jahan, N., Khan, H., Shaekh Md, P. E., Islam Md, A., . . . Rahman, M. (2014). Efficient in vitro micropropagation of gynura procumbens - an important rare medicinal plant, through shoot tip and nodal segment explants. Journal of research in biology, 4(6), 1444-1450.
2014 Islam, M. A., Alam, M. J., Urmee, S. A., Rahaman, M. H., Razu, M. H., & Mazumdar, R. M. (2014). Isolation, identification, in vitro antibiotic resistance and plant extract sensitivity of fire blight causing erwinia amylovora. Journal of plant pathology & microbiology, 5(3), 1-4.
DOI
2012 Razu, M. H., Zaman, S., Akhter, R., Rahman, M. M., Rahaman, M. H., Mazid, M. A., & Kabir, G. (2012). Morphological and cytological effects of two herbicides on tetraploid wheat (Triticum durum L.). Journal of bio-science, 20(0), 143-151.
DOI Scopus4
2011 Zaman, R., Karmaker, P., Hasan, S. M. N., Rahman, M. H., & Haque, A. (2011). Drifted catalytic properties of β-lactamases due to unconstrained use of antibiotics. Journal of bio-science, 19, 37-42.
DOI

Year Citation
2024 Bantie, L., Likisa, J., Rahaman, M., Teo, T., Safaroghliazar, A., Basnet, S. K. C., . . . Wang, S. (2024). AU2-94: A CDK4-specific inhibitor with the marked anti-tumor efficacy. In CANCER RESEARCH Vol. 84 (pp. 2 pages). CA, San Diego: AMER ASSOC CANCER RESEARCH.
DOI
2019 Rahaman, M. H., Zhang, Y., Islam, M. S., Heinemann, G., Anshabo, A. T., Albrecht, H., . . . Wang, S. (2019). LS007, a potent and orally bioavailable CDK9 inhibitor, suppresses the growth of triple-negative and estrogen receptor-positive breast cancer. In CANCER RESEARCH Vol. 79 (pp. 2 pages). GA, Atlanta: AMER ASSOC CANCER RESEARCH.
DOI
2017 Tadesse, S., Bantie, L., Tomusange, K., Islam, S., Rahaman, M. H., Noll, B., . . . Wang, S. (2017). CDKI-15, a novel and highly selective CDK4/6 inhibitor: discovery, <i>in vitro</i> and <i>in vivo</i> anticancer efficacy. In CANCER RESEARCH Vol. 77 (pp. 2 pages). DC, Washington: AMER ASSOC CANCER RESEARCH.
DOI

  • Targeting cyclin-dependent kinase 4 in glioblastoma, Neurosurgical Research Foundation, 24/08/2020 - 21/08/2021

Date Role Research Topic Program Degree Type Student Load Student Name
2025 Co-Supervisor - Doctor of Philosophy Doctorate Full Time Mr Ming Phong

Connect With Me

External Profiles

Other Links